Sumo is commonly used to provide supportive relief that helps ease the overall symptom burden in conditions characterized by periods of heightened symptoms involving inflammatory or irritative processes.

---

What Sumo Treats: Main Uses and Benefits

The therapeutic use is considered relevant for managing symptoms associated with acute or episodic changes, including those linked to acute pain, painful osteoarthritis, and primary dysmenorrhoea (menstrual pain). This therapeutic domain may assist with managing symptoms related to physical discomfort and inflammation, such as those related to inflammatory or irritative states.

It is generally applied in clinical settings that involve acute or unstable symptom patterns where short-term symptomatic assistance is needed. This focus on short-term use may contribute to improved comfort during temporary episodes of heightened discomfort.

“This approach may help patients cope more steadily with symptom fluctuations.”

The support provides relief when symptoms interfere with routine activities, playing a role in managing symptoms that create noticeable physiological strain.

---

Quick Fact: Symptomatic Support for Acute Pain

Regulatory References

1. European Medicines Agency's official document on Nimesulide

Eligibility Map: Who can and cannot use Sumo — Official Regulatory Information

The eligibility profile for Sumo (Phenothrin), a topical ectoparasiticide, is strictly defined by government regulatory documents based on patient status and specific conditions of use. Use is contraindicated in individuals with a documented history of hypersensitivity or allergy to pyrethroid insecticides (the chemical class of Phenothrin) or any of the product's excipients.

Eligibility Scope

Eligibility Status	Population/Condition
Use is Allowed	Adults, the elderly, and children aged 6 months and above under standard labeled conditions.
Use is Contraindicated	Individuals with hypersensitivity to pyrethroid insecticides or product ingredients.
Use is Restricted	Children under 6 months of age (requires medical supervision).

Specific Eligibility Restrictions

• Age-Based Limitations: While standard use is for those 6 months and older, the use in infants younger than 6 months is not established for standard retail use and is restricted to under medical supervision only.
• Condition-Based Rules: The medicine must not be used on broken or secondarily infected skin. Use also requires caution in patients with pre-existing conditions like asthma or severe eczema due to potential excipient-related effects.
• Physiological Status: Use during pregnancy or lactation is authorized but should be carried out with caution.

Official Eligibility Statement: Regulatory documents mandate that individuals with known hypersensitivity are contraindicated, and use in infants under 6 months is restricted, defining the boundaries for who is eligible to use the product.

Interactions with other medicines and products

Official Regulatory Profile Status

The official interaction profile for Phenothrin (Sumo), an ectoparasiticide administered topically, is characterized by a general absence of specific, documented systemic drug-drug interactions in authoritative government regulatory information. This status is consistent with the medicine's route of administration, which results in minimal to negligible systemic absorption of the active ingredient.

Interaction Type	Officially Documented Status
Formal Contraindications	None listed for co-administration with specific medicinal products.
Metabolic (CYP) / Transporter Interactions	None documented.
Timing Requirements	No mandatory time separation from other medicines is required.

Regulatory Advice on Co-Administration

Official regulatory documents impose no specific timing-based rules or formal restrictions related to systemic exposure. No particular medicinal products, foods, or herbal supplements are explicitly identified in official labeling as causing a formal pharmacokinetic or pharmacodynamic interaction. However, regulatory sheets may advise general caution regarding the concurrent use of other topical products, over-the-counter medicines, and dietary supplements.

Direct Modulation of Parasite Sodium Channels

Sumo (Phenothrin) exerts its action by selectively targeting voltage-gated sodium channels (VGSCs) in the nerve membranes of the ectoparasites. It acts as a channel modulator, binding to the channel protein and impairing its ability to close properly. This molecular interaction sustains the channel in an open state, initiating a continuous cascade of electrical activity.

---

Neurotoxic Cascade and System Overload

The continuous failure of the sodium channels to inactivate causes a sustained influx of sodium ions into the nerve cell, resulting in hyperexcitation and repetitive nerve discharge. This neural overload rapidly compromises the parasite's motor control pathways, leading to immediate muscular spasms and irreversible paralysis (the knockdown effect).

---

️ Mechanisms of Pharmacodynamic Constraint

The drug's mechanism can be physiologically constrained, primarily by two factors: target site resistance (e.g., Kdr mutations) which structurally alter the VGSC to reduce Phenothrin's binding affinity, and metabolic detoxification via enhanced parasitic enzyme activity. These constraints limit the duration of system overload and resulting in a reduced physiological consequence.

How to Use Sumo (Phenothrin) — Official Administration Guidelines

Administration Scope

Feature	Guideline
Route of administration	Topical application to the hair and scalp (dermal/cutaneous use).
Dosing schedule	The product is applied liberally to the infested area until the entire scalp and hair is thoroughly moistened/saturated. Specific concentrations, such as 0.2% w/v solutions or 0.5% mousses, are used according to labeled protocols.
Age-group administration rules	Approved for use in adults, the elderly, and children aged 6 months and above. Treatment of children under 6 months should only occur under medical supervision.
Special procedural conditions	The product is applied to dry hair. It must be allowed to dry naturally, and no artificial heat (e.g., electric hairdryer) or naked flames should be used during or immediately after application. Hair may be washed with a normal shampoo 2 hours after application.

---

Instruction Classifications (High-Level)

Classification	Description
Administration method type	Topical application only.
Frequency pattern	Course-based. Treatment should not exceed one application per week.
Use-context constraints	External use only. Must remain on the hair for the required contact time before rinsing.

---

Resulting Procedural Structure

Official step sequence:

• Apply the topical formulation liberally to dry hair until the area is saturated.
• Allow the product to dry naturally on the hair for the specific contact time defined in the product label.
• Rinse the hair thoroughly with warm water and wash with a normal shampoo after the prescribed time has elapsed.
• Re-treat the infested area with the same procedure 7 days after the initial application, but only if live parasites are observed.

Connection to the overall use protocol (2–4 sentences): The official administration protocol for Phenothrin establishes a standardized, non-systemic, topical contact treatment defined by the need to fully saturate the hair and scalp. This approach mandates a specific contact time before rinsing and includes a structured re-treatment application 7 days later as a key step in the protocol for addressing the full life cycle of the target organisms. These instructions structure the usage as a short-term, two-part course of administration, limiting the maximum application frequency.

Research evidence / Overview of studies for Sumo

Evidence Base for Ectoparasitic Conditions (Head Lice)

Research concerning the Phenothrin active agent in Sumo primarily involves short-term Randomized Controlled Trials (RCTs) and systematic reviews exploring parasitic infestations. Studies included both children and adults and focused on the measured absence of live lice shortly after treatment. Findings describe patterns observed in these short-term studies, but long-term effects are not fully established, and the influence of factors like parasite resistance remains uncertain.

Research Evidence for Acute Symptom Management

Research has also explored the agent in the context of acute or episodic pain and primary dysmenorrhoea (menstrual pain), relying mainly on short-term RCTs in adult populations. These trials examined measured outcomes related to acute symptom changes, physical discomfort, and functional ability, reporting patterns related to measured changes over very short time intervals.

Evidence Gaps and Limitations

Across all indications, the research is characterized by a focus on short-term evaluation. This means long-term outcomes are not well characterized, as studies were only conducted for limited durations (often ≤ 15 days for acute pain management). Data for certain special populations, such as infants under six months or the elderly, remain insufficient. Regulatory summaries note that the evidence quality varies across studies, and research highlights that the results apply only to the specific populations studied.

Key Studies & References Comparison of phenothrin mousse, phenothrin lotion, and wet-combing for treatment of head louse infestation in the UK: a pragmatic randomised, controlled, assessor blind trial

Common questions about Sumo (FAQ)

---

Q: Is Sumo only available by prescription?

Preparations containing the active ingredient Phenothrin (Sumo) for the treatment of ectoparasites are typically classified as non-prescription, or over-the-counter (OTC), medicines. This classification means they are generally available without a healthcare provider's prescription in topical forms.

---

Q: Where can I find the official regulatory labeling information for Sumo?

Official regulatory information is provided by national health authorities and governmental drug agencies. Documents like the Summary of Product Characteristics (SmPC) or the FDA-approved drug label can be found through resources such as the DailyMed drug database or the websites of these national health authorities.

---

Q: Do side effects from Sumo typically decrease after a period of use?

The common local reactions associated with topical use, such as skin tingling, itching, or a burning sensation, are typically transient. Product information suggests these temporary contact effects may resolve within 48 hours after exposure.

---

Q: What is the typical time frame for the initial effects of Sumo to be observed?

The active ingredient in Sumo works by causing rapid neurotoxicity in the parasite's nervous system. Due to this swift mechanism of action, the product is designed to cause immediate paralysis, known as the 'knockdown effect,' of the target organisms upon contact.

---

Q: How long is the effect of a single dose of Sumo described as lasting?

The official product protocol establishes the treatment as a two-part course designed to address the full life cycle of the target organism. A second application is recommended 7 days after the first, but only if live parasites are still observed, indicating that the initial treatment's efficacy supports the intervening period.

---

Q: What is known about the transfer of Sumo into breast milk?

Official information states that use during lactation requires caution. Due to the minimal systemic absorption of the topical application, it is not known whether the active ingredient is excreted in human breast milk.

---

Q: Are there specific warnings for older adults using Sumo?

Regulatory documents confirm that the product is approved for use in the elderly population under standard conditions. There are generally no specific warnings or mandatory dosage adjustments mandated uniquely for older adults.

---

Q: What is the difference between the brand name and the generic version of Sumo?

According to regulatory principles, a generic product must contain the identical active ingredient (Phenothrin) as the brand name product (Sumo). Both the generic and brand name must be equivalent in strength and dosage form and meet the same strict regulatory standards for quality and performance.

---

Q: Why do some people report feeling restless after starting Sumo?

The official safety profile includes nervous system disorders such as headache, dizziness, and fatigue among the noted effects. However, restlessness is not explicitly listed in regulatory documents as a known side effect of the product.

---

Q: What are the signs of a serious allergic reaction to Sumo as listed in official warnings?

The product is officially contraindicated for individuals with known hypersensitivity or allergy to pyrethroids. Signs suggesting a severe allergic reaction, such as swelling of the face or difficulty breathing, are listed as reasons to stop use and seek prompt medical attention.

---

Q: Is there a maximum official duration for using Sumo?

The official guidelines define the use of Sumo as a short-term, course-based treatment. The administration protocol limits application frequency, stating that treatment should not exceed one application per week, structuring the use as a defined, limited two-part application course.

---

Q: What happens if a dose of Sumo is missed?

The standard protocol involves a single re-treatment application 7 days after the initial dose, which is only necessary if live parasites are still observed. If the second planned application is missed, re-treatment is only indicated if live parasites are observed to persist, following the standard re-treatment procedure.

---

Q: What is the significance of the 'black box warning' mentioned for certain medications?

A Boxed Warning, often called a 'Black Box Warning,' represents the most serious warning required by the FDA on drug labeling. It is included when there is reasonable evidence of a serious or life-threatening adverse effect associated with the drug.

---

Q: Why is Sumo sometimes confused with other drugs that have similar names?

Sumo contains the active ingredient Phenothrin, which is also identified by the synonym Sumithrin. This similar terminology, common among products of the pyrethroid class, may lead to confusion with other drugs that share similar names or brand identifiers.

---

Q: Does Sumo interact with common medications used for high blood pressure?

Official regulatory documents note a general absence of specific, documented systemic drug-drug interactions, even with common medications like those for high blood pressure. This is because the topical route of administration results in minimal to negligible absorption of the active ingredient into the bloodstream.

---

Q: What official information is available on the potential for overdose with Sumo?

Serious adverse reactions and potential toxicity are restricted to scenarios involving exposure far exceeding the intended topical use, such as accidental ingestion. These events may lead to severe neurological symptoms or gastrointestinal issues like nausea and vomiting.

How to Store and Dispose of Sumo (Phenothrin Topical)

Official regulatory information mandates specific conditions for storing and disposing of Phenothrin-containing products to ensure stability and environmental safety.

---

Storage Requirements

Condition	Requirement
Temperature	Store at room temperature (20 C to 25 C); avoid extreme heat

. | | Protection | Keep in the original container, tightly closed, and protect from direct sunlight and moisture. | | Child Safety | Keep out of reach of children and pets. |

---

Disposal Instructions

Do not pour the product down the drain or flush it, as the active ingredient is toxic to aquatic life. Unused or expired medicine should be disposed of through a drug take-back program. If unavailable, mix the product with an undesirable substance (like coffee grounds), seal it in a container, and discard it in household trash, following local guidelines.